A Trial of Gemcitabine, Pembrolizumab and IMM-101 as First Line Treatment in Patients With Metastatic Pancreatic Cancer

Clinical trial NCT06498518 · WITHDRAWN

Trial details

NCT number: NCT06498518
Sponsor: Karen Carty
Status: WITHDRAWN
Phase: Phase 2
Study type: INTERVENTIONAL

Neoplasms Pancreatic

Start date: 2024-06-17
Primary completion: 2025-05-23
Enrollment: 0

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.